BRPI0812775A2 - Derivado de 5beta, 14beta-androstano úteis para o tratamento de reestenose após angioplastia ou endoarterectomia e doenças devido à fibrose de órgãos - Google Patents

Derivado de 5beta, 14beta-androstano úteis para o tratamento de reestenose após angioplastia ou endoarterectomia e doenças devido à fibrose de órgãos

Info

Publication number
BRPI0812775A2
BRPI0812775A2 BRPI0812775-1A2A BRPI0812775A BRPI0812775A2 BR PI0812775 A2 BRPI0812775 A2 BR PI0812775A2 BR PI0812775 A BRPI0812775 A BR PI0812775A BR PI0812775 A2 BRPI0812775 A2 BR PI0812775A2
Authority
BR
Brazil
Prior art keywords
endoarterectomy
14beta
5beta
angioplasty
restenosis
Prior art date
Application number
BRPI0812775-1A2A
Other languages
English (en)
Inventor
Liberato Berrino
Antonio Cascino
Marilena Cipollaro
Amalia Forte
Francesco Rossi
Giuseppe Bianchi
Patrizia Ferrari
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of BRPI0812775A2 publication Critical patent/BRPI0812775A2/pt
Publication of BRPI0812775B1 publication Critical patent/BRPI0812775B1/pt
Publication of BRPI0812775B8 publication Critical patent/BRPI0812775B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0812775A 2007-06-07 2008-06-04 uso de 17 beta-(3-furil)-5 beta-androstano-3 beta, 14 beta, 17 alfa- triol na preparação de um medicamento para prevenção ou tratamento de doenças devidas à fibrose hepática BRPI0812775B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109779 2007-06-07
PCT/EP2008/056928 WO2008148812A1 (en) 2007-06-07 2008-06-04 5beta, 14beta-androstane derivatives useful for the treatment of restenosis after angioplastic or endoartherectomy and diseases due to organ fibrosis

Publications (3)

Publication Number Publication Date
BRPI0812775A2 true BRPI0812775A2 (pt) 2014-12-02
BRPI0812775B1 BRPI0812775B1 (pt) 2020-02-04
BRPI0812775B8 BRPI0812775B8 (pt) 2021-05-25

Family

ID=38662675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812775A BRPI0812775B8 (pt) 2007-06-07 2008-06-04 uso de 17 beta-(3-furil)-5 beta-androstano-3 beta, 14 beta, 17 alfa- triol na preparação de um medicamento para prevenção ou tratamento de doenças devidas à fibrose hepática

Country Status (18)

Country Link
US (1) US20100303896A1 (pt)
EP (1) EP2160190B1 (pt)
JP (1) JP5579058B2 (pt)
KR (1) KR101530019B1 (pt)
CN (1) CN101720224B (pt)
AU (1) AU2008258521B2 (pt)
BR (1) BRPI0812775B8 (pt)
CA (1) CA2688079C (pt)
DK (1) DK2160190T3 (pt)
ES (1) ES2556731T3 (pt)
HR (1) HRP20151233T1 (pt)
HU (1) HUE025599T2 (pt)
MX (1) MX2009012917A (pt)
PL (1) PL2160190T3 (pt)
PT (1) PT2160190E (pt)
RS (1) RS54459B1 (pt)
SI (1) SI2160190T1 (pt)
WO (1) WO2008148812A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1012240A2 (pt) 2009-03-23 2018-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW226375B (pt) * 1991-10-24 1994-07-11 American Home Prod
WO1993015734A1 (en) * 1992-02-14 1993-08-19 Warner-Lambert Company Method of treating abnormal tissue proliferation by administering an angiotensin ii antagonist
DE4227616C2 (de) * 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
DE4232638C2 (de) * 1992-09-29 1994-11-17 Sigma Tau Ind Farmaceuti 17-Phenyl-5beta-14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DK0618207T3 (da) * 1993-03-24 1999-08-30 American Home Prod Substituerede pyridopyrimidiner som antihypertensiva
WO2004089416A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US20060135443A1 (en) 2004-10-18 2006-06-22 Bionaut Pharmaceuticals, Inc. Use of Na*/K*-ATPase inhibitors and antagonists thereof

Also Published As

Publication number Publication date
WO2008148812A1 (en) 2008-12-11
EP2160190A1 (en) 2010-03-10
JP5579058B2 (ja) 2014-08-27
MX2009012917A (es) 2010-01-14
HUE025599T2 (en) 2016-05-30
HK1140698A1 (en) 2010-10-22
JP2010529082A (ja) 2010-08-26
PT2160190E (pt) 2016-01-27
CA2688079A1 (en) 2008-12-11
CN101720224B (zh) 2014-03-26
ES2556731T3 (es) 2016-01-19
HRP20151233T1 (hr) 2015-12-18
CA2688079C (en) 2016-05-03
AU2008258521B2 (en) 2013-03-28
AU2008258521A1 (en) 2008-12-11
US20100303896A1 (en) 2010-12-02
PL2160190T3 (pl) 2016-03-31
DK2160190T3 (en) 2016-01-11
SI2160190T1 (sl) 2015-12-31
BRPI0812775B8 (pt) 2021-05-25
CN101720224A (zh) 2010-06-02
RS54459B1 (sr) 2016-06-30
EP2160190B1 (en) 2015-11-04
BRPI0812775B1 (pt) 2020-02-04
KR20100022021A (ko) 2010-02-26
KR101530019B1 (ko) 2015-06-18

Similar Documents

Publication Publication Date Title
CY2020032I2 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
PT2641596T (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
BRPI0814105A2 (pt) Métodos e composições para o tratamento de hipertensão pulmonar e doenças e distúrbios relacionados
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
CY2024014I1 (el) Μη-ορμονικοι στεροειδεις ρυθμιστες toy nf-kb για θεραπεια ασθενειας
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0917013A2 (pt) métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
BRPI0911518A2 (pt) novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao estresse de célula
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0906492A2 (pt) antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
PT3045474T (pt) Agentes terapêuticos para o tratamento de doenças associadas à proliferação celular indesejada
BR112012002578A2 (pt) composição para o tratamento da fibrose cística
BRPI0906618A2 (pt) Derivados de diazepinorimidona de arilamida substituídos para o tratamento de doenças neu-rodegenerativas causadas por atividade anorma de gsk3-beta
PT2307000E (pt) Associação de pilocarpina e metimazol para o tratamento da doença de charcot-marie-tooth e patologias relacionadas
BRPI0920617A2 (pt) pílula gota para tratamento de doença de coronária de coração e sua preparação
IL200091A0 (en) Use of chitosans for the treatment of nail inflammatory diseases
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
BRPI0915927A2 (pt) uso de inibiodores de hdac para o tratamento da doença de hodgkin
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: CVIE THERAPEUTICS LIMITED (TW)

B25A Requested transfer of rights approved

Owner name: CVIE THERAPEUTICS LIMITED (TW)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2777 DE 26-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.